Error in Figures 3 and 4
In the original publication [1], there was a mistake in Figures 3 and 4 as published. The contents of Figures 3 and 4 have been swapped. The corrected Figure 3 and Figure 4 appear below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Figure 3.
Six selected DEGs between CAFs and NFs. (A) Heatmap of six selected DEGs between CAFs and NFs. (B) Boxplot of DEGs comparing CAFs and NFs. Adjusted p-values (FDR) from generalized linear model. COL11A1 and TNC, known fibroblast markers; GREM1, BMP pathway; CD36, antigen processing machinery pathway; CXCL2, chemokine pathway; and GAS6, hypoxia pathway. (C) Boxplot of DEGs comparing LN-CAFs, Lung-CAFs, and NFs. (D) Western blot analysis (left) and densitometry-based quantification (right) of GREM-1 and GAS6 in LN-CAFs, Lung-CAFs, and NFs derived from squamous cell carcinomas, adenocarcinomas, and non-tumorous lungs. Adjusted p-values (FDR): ns, p > 0.05; ****, and p ≤ 0.0001. CAF, cancer-associated fibroblast; NF, normal fibroblast; SqCC, squamous cell carcinoma; and ADC, adenocarcinoma.
Figure 4.
DEG sets between CAFs and NFs. (A) Heatmap of GSVA scores in selected DEG sets among well-known pathway databases (e.g., HALLMARK, BIOCARTA, KEGG, REACTOME, and WIKI pathway). (B) Boxplot of GSVA scores in selected DEG sets comparing CAFs and NFs. Gene sets related to hypoxia responses (Hallmark Hypoxia) and EMT (Hallmark EMT) were upregulated in CAFs compared with NFs (all FDR, p ≤ 0.0001). Conversely, the gene set related to mismatch repair (Reactome Mismatch Repair) exhibited significantly higher GSVA scores in NFs than in CAFs (FDR, p ≤ 0.0001). (C) Boxplot of GSVA scores in selected DEG sets comparing LN-CAFs, Lung-CAFs, and NFs. LN-CAFs showed higher GSVA scores for gene sets such as Hallmark Hypoxia and Hallmark EMT, compared with Lung-CAFs (FDR, p ≤ 0.0001). Adjusted p-values (FDR): *, p ≤ 0.05; ***, p ≤ 0.001; ****, and p ≤ 0.0001. CAF, cancer-associated fibroblast; EMT, epithelial–mesenchymal transition; NF, normal fibroblast; and GSVA, gene set variation analysis.
Reference
- Kim, B.-G.; Park, K.; Hwang, M.; Lee, H.; Park, K.-M.; Choe, J.; Shin, S.H.; Jeong, B.-H.; Lee, K.; Lee, J.; et al. Identification of GREM-1 and GAS6 as Specific Biomarkers for Cancer-Associated Fibroblasts Derived from Patients with Non-Small-Cell Lung Cancer. Cancers 2025, 17, 2858. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.